Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
|NCT02166905||II||NY-ESO-1+ or LAGE-1+ ovarian cancer with or without residual disease after treatment||A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen||NY||View Drugs||View Results |
|CDX-1401||DEC-205/NY-ESO-1 fusion protein CDX-1401||Immune response against cancer expressing NY-ESO-1||Clinical Trials|
|Epacadostat||IDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360||Inhibits IDO1 to stimulate immune response||Clinical Trials|
|NCT04239014||II||Recurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapy||A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment||Contact research study staff||View Drugs|
|Ceralasertib||AZD6738, ATR kinase inhibitor AZD6738||ATR kinase inhibitor||Clinical Trials|
|Olaparib||AZD2281, Lynparza||PARP inhibitor||Approved in Ovarian Cancer|